Novelion Therapeutics Inc. (NVLN) Trades at $3.00 After Triangle; Chemocentryx (CCXI) Shorts Decreased By 2.85%




August 20, 2018 – By Tyler Harlow

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Chemocentryx Inc (NASDAQ:CCXI) had a decrease of 2.85% in short interest. CCXI’s SI was 2.45 million shares in August as released by FINRA. Its down 2.85% from 2.52 million shares previously. With 277,400 avg volume, 9 days are for Chemocentryx Inc (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Inc’s float is 11.45%. The stock increased 0.73% or $0.08 during the last trading session, reaching $11.03. About 163,923 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since August 20, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 ChemoCentryx 4Q EPS 80c; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10

Novelion Therapeutics Inc. (NVLN) formed triangle with $3.12 target or 4.00% above today’s $3.00 share price. Novelion Therapeutics Inc. (NVLN) has $56.56 million valuation. The stock decreased 0.66% or $0.02 during the last trading session, reaching $3. About 6,797 shares traded. Novelion Therapeutics Inc. (NASDAQ:NVLN) has declined 55.52% since August 20, 2017 and is downtrending. It has underperformed by 68.09% the S&P500. Some Historical NVLN News: 10/05/2018 – NOVELION THERAPEUTICS INC QUARTERLY NET LOSS PER SHARE $1.76; 15/03/2018 Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital; 15/03/2018 – NOVELION THERAPEUTICS SAYS THE FINANCING FACILITY PROVIDES FOR A $20 MLN TERM LOAN TO CO’S UNIT AEGERION PHARMACEUTICALS; 15/03/2018 – Novelion Therapeutics 4Q Loss $24.6M; 15/03/2018 – Novelion Therapeutics 4Q Loss/Shr $1.32; 15/03/2018 – NOVELION THERAPEUTICS SAYS ITS UNIT HAS ENTERED INTO A NEW SECURED FINANCING FACILITY WITH AFFILIATES OF SARISSA CAPITAL AND BROADFIN CAPITAL; 15/03/2018 – Novelion Therapeutics 4Q Rev $38.9M; 10/05/2018 – Novelion Therapeutics 1Q Loss $32.8M; 31/03/2018 – Novelion Therapeutics Supports World Lipodystrophy Day; 10/05/2018 – Novelion Therapeutics 1Q Loss/Shr $1.76

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. ChemoCentryx had 5 analyst reports since March 13, 2018 according to SRatingsIntel. The stock has “Overweight” rating by JP Morgan on Tuesday, March 13. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Neutral” rating given on Tuesday, August 14 by JP Morgan.

Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It turned negative, as 10 investors sold ChemoCentryx, Inc. shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Piermont Management, Missouri-based fund reported 22,960 shares. 521,864 are owned by Acadian Asset Mgmt Llc. Dekabank Deutsche Girozentrale stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Thompson Davis Inc accumulated 625 shares or 0.02% of the stock. 53,810 are held by Federated Inc Pa. Savings Bank Of Montreal Can holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 10,828 shares. Smith Asset Mgmt Ltd Partnership holds 0.01% or 26,447 shares in its portfolio. Proshare Limited Liability Corp invested in 0% or 25,705 shares. 85,137 were accumulated by Commercial Bank Of America De. Keybank National Association Oh holds 0% or 45,740 shares in its portfolio. Legal And General Grp Public Ltd Co owns 4,583 shares or 0% of their US portfolio. Price T Rowe Associates Md stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Blackrock Incorporated holds 0% or 2.57 million shares. Geode Management Ltd Liability Company holds 259,558 shares or 0% of its portfolio. Spark Invest Mgmt Limited Liability holds 62,600 shares.

Since May 1, 2018, it had 0 insider buys, and 12 selling transactions for $7.89 million activity. Schall Thomas J. sold $152,028 worth of stock or 10,857 shares. Cappel Markus J. sold $344,201 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) on Wednesday, June 27. The insider KANAYA SUSAN M sold 99,507 shares worth $1.34 million.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $555.68 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 32.93 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *